LFB, in the service of French healthcare sovereignty
LFB has a public health mission*: to provide, as a priority for healthcare professionals and patients in France, medicinal products of major therapeutic interest, essential to patients’ lives. In this way, LFB contributes to strengthening France’s healthcare and industrial sovereignty in plasma-derived medicinal products.
LFB meets the growing needs for bioproduction in France: with considerable investments in the production of innovative medicinal products and treatments. With the construction of the Arras site and extension of the Alès site, LFB and its more than 2,800 employees also contribute to dynamic national and regional economic activity in the Hauts-de-France, Occitanie and Île-de-France regions of France.
*Article L.5124-14 of the French Public Health Code, modified in 2015 by Article 190 of French Act No. 2015-990.
Dynamic regional and national economic activity, with four sites located in France:
Located in the Essonne department of France, the Les Ulis plant specialises in the upstream steps of the production processes for plasma-derived medicinal products, from receipt of the bags of plasma to the intermediate products.
More than 1,000 employees
The Lille plant specialises in the downstream steps of the production processes for plasma-derived medicinal products, from the receipt of intermediate products to aseptic filling of the medicinal products into vials.
The Carvin site is the packaging site for LFB’s liquid products.
More than 770 employees
As a CDMO (Contract Development and Manufacturing Organisation) with US FDA (Food and Drug Administration) approval, the Alès site, LFB BIOMANUFACTURING, shares its know-how and equipment with customers, including support for the development of cell lines and processes on an industrial scale, the manufacture of clinical and commercial batches and even the associated analytical testing. As an essential part of LFB’s activities, it is specialised in the bioproduction of therapeutic proteins, and of monoclonal antibodies in particular, by cell culture.
75 employees today
and more than 120 in 2026
The Arras plant will start operations by the end of 2024, and will ultimately triple LFB’s production capacity, by tripling its plasma fractionation capacity. This 11,000 square meter plant will produce immunoglobulins, fibrinogen and albumin, medicinal products for which demand is growing in France and around the world. Designed in particular to optimise production costs and to meet the highest global standards, this new site will allow LFB to produce in France for the entire world.
300 employees to date and more than 600 in 2028.
LFB is a member of G5 Santé
G5 Santé brings together the leaders of eight French healthcare companies, including Jacques Brom, CEO of LFB. Its ambition is to strengthen France's scientific, economic, social and regulatory ecosystem to facilitate innovation, industrial development and patient access to innovative health products, and biomedicinal products in particular.
It also aims to make more therapeutic and diagnostic solutions available to patients.
